Cytogenomic assessment of the diagnosis of 93 patients with developmental delay and multiple congenital abnormalities: The Brazilian experience

OBJECTIVE: The human genome contains several types of variations, such as copy number variations, that can generate specific clinical abnormalities. Different techniques are used to detect these changes, and obtaining an unequivocal diagnosis is important to understand the physiopathology of the diseases. The objective of this study was to assess the diagnostic capacity of multiplex ligation-dependent probe amplification and array techniques for etiologic diagnosis of syndromic patients. METHODS: We analyzed 93 patients with developmental delay and multiple congenital abnormalities using multiplex ligation-dependent probe amplifications and arrays. RESULTS: Multiplex ligation-dependent probe amplification using different kits revealed several changes in approximately 33.3% of patients. The use of arrays with different platforms showed an approximately 53.75% detection rate for at least one pathogenic change and a 46.25% detection rate for patients with benign changes. A concomitant assessment of the two techniques showed an approximately 97.8% rate of concordance, although the results were not the same in all cases. In contrast with the array results, the MLPA technique detected ∼70.6% of pathogenic changes. CONCLUSION: The obtained results corroborated data reported in the literature, but the overall detection rate was higher than the rates previously reported, due in part to the criteria used to select patients. Although arrays are the most efficient tool for diagnosis, they are not always suitable as a first-line diagnostic approach because of their high cost for large-scale use in developing countries. Thus, clinical and laboratory interactions with skilled technicians are required to target patients for the most effective and beneficial molecular diagnosis

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Study of copy number variations (CNVs) of subtelomeric regions in patients with congenital malformations and intellectual disabilities

A variação no número de cópias gênicas (CNVs) é a alteração estrutural mais prevalente no genoma humano. Estas alterações estão presentes em alta proporção nos subtelômeros, quando comparados com o resto do genoma. Isso ocorre principalmente porque essas regiões são ricas em genes e porque apresentam sequências repetitivas que as tornam suscetíveis a rearranjos genômicos. Na literatura os rearranjos subteloméricos, como deleções, duplicações e translocações estão associados à etiologia da deficiência intelectual (DI), do atraso no desenvolvimento neuropsicomotor (ADNPM) e das malformações congênitas (MC). Estudos prévios com pacientes com DI revelaram taxas de CNVs patogênicas em regiões subteloméricas variando de 2,4% a 4,8%. Os objetivos desse trabalho foram: investigar a presença das CNVs subteloméricas nos pacientes portadores de malformações congênitas e deficiência intelectual, caracteriza-las quanto a extensão e patogenicidade e sugerir os mecanismos produtores dessas alterações. Foram analisadas 105 amostras de DNA de pacientes com DI/ADNPM associada a MC. Utilizamos a técnica de MLPA (Multiplex Ligation-dependent Probe Amplification) com kits específicos para regiões subteloméricas (P036 e P070). Dentre os pacientes que apresentaram alterações pela técnica de MLPA, 7 pacientes foram submetidos à técnica de array, utilizando as plataformas Agilent SurePrint G3 Genoma Humano microarray 180 K e HumanCytoSNP-12 BeadChip Illumina®. O MLPA permitiu identificar alterações subteloméricas em 14,28% dos casos, sendo 7 pacientes com uma deleção isolada, 7 pacientes apresentaram uma deleção concomitante a uma duplicação e um paciente apresentou duas duplicações. A análise por array confirmou as alterações encontradas por MLPA e permitiu a delimitação acurada dos pontos de quebra genômicos. A análise combinada utilizando bioinformática com diferentes ferramentas: DGV (Database of Genomic Variants), DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources), UCSC Genome Bioinformatics e DAVID (Database for Annotation, Visualization and Integrated Discovery), revelou um total de 8 genes sugestivos de serem responsáveis por fenótipos clínicos distintos. Dentre eles, o gene DIAPH1 foi relacionado à microcefalia, o gene CTNND2 à DI e o gene OTOS à surdez. O array revelou elementos repetitivos, sequências teloméricas e/ou STRs nas regiões próximas aos pontos de quebra estudados. Também nos permitiu inferir que os pontos de quebra com deleção simples são sugestivos de NHEJ ou MMEJ e os casos que apresentaram rearranjos complexos: FoSTeS ou MMBIR. A estratégia teve sucesso em identificar CNVs subteloméricas e associá-las ao fenótipo dos pacientes e, adicionalmente, possibilitou a sugestão dos mecanismos que as produziramCopy number variation (CNV) is the most prevalent structural changes in the human genome. These changes are present in a high rate in subtelomere compared with the rest of the genome. This is primarily because these regions are gene rich and because of the presence of repetitive sequences that make them susceptible to genomic rearrangements. Subtelomeric rearrangements, such as deletions, duplications and translocations are associated with the etiology of intellectual disability (ID), the developmental delay (DD) and congenital malformations (CM). Previous studies with patients with ID have revealed rates of pathogenic CNVs in subtelomeric regions ranging from 2.4% to 4.8%. The objectives of this study were to investigate the presence of subtelomeric CNVs in patients with congenital malformations and intellectual disability, characterized them as the extent and pathogenicity and suggest mechanisms of formation. DNA samples from 105 patients with ID/DD associated with CM were analysed. We use the MLPA (Multiplex Ligationdependent Probe Amplification) technique with specific subtelomeric regions (P036 and P070) kits. Among patients with CNVs changes by MLPA, seven were submitted to array technique, using Agilent SurePrint G3 Human Genome microarray HumanCytoSNP or 180 K-12 BeadChip Illumina® platforms. The subtelomeric MLPA analysis identified alterations in 14.28% of cases, 7 patients presented an isolated deletion, 7 patients presented a concomitant deletion and duplication and 1 patient presented two duplications. The array analysis confirmed the alterations found by MLPA and allowed the accurate delineation of the genomic break points. The analysis combined with bioinformatics using different tools: DGV (Database of Genomic Variants), Decipher (Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources), UCSC Genome Bioinformatics and DAVID (Database for Annotation, Visualization and Integrated Discovery), revealed a total of eight genes that are suggestible responsible for distinct clinical phenotypes. Among them, DIAPH1 gene was related to microcephaly, CTNND2 gene to ID and OTOS gene to deafness. Array revealed repetitive elements, telomeric sequences and / or STR close to breakpoints regions. We propose that the breakpoints with single deletions are suggestive of NHEJ or MMEJ and cases with complex rearrangements: FoSTeS or MMBIR. This strategy could identify subtelomeric CNVs, improve the genotype-phenotype association and also allowed the investigation of mechanisms for formatio

Next Generation Sequencing of DNA breakpoints for investigation of formation mechanisms in genomic rearrangements

Rearranjos genômicos são alterações estruturais na molécula de DNA e podem ser a causa de inúmeras doenças genéticas. O mecanismo gerador dessas alterações é bem variável. Ele pode ser recorrente, por intermédio de low copy repeats (LCRs), resultando num rearranjo causado por recombinação homóloga não-alélica (NAHR), ou não recorrente, ou seja, sem intermédio de um hotspot. Dentre os mecanismo não recorrentes temos: a junção das extremidades não-homólogas (NHEJ - non-homologous end joining) e a junção mediada por micro-homologia (MMEJ - microhomology-mediated end joining), a replicação em série por deslizamento (SRS), a SRS induzida por quebra (BISRS), a replicação induzida pela quebra de DNA por homologia (MMBIR - microhomology-mediated break induced replication), o enrolamento da forquilha de replicação e mudança de molde de DNA (FoSTeS - fork stalling and template switching). A análise dos pontos de quebra dos rearranjos genômicos pode fornecer informações importantes para uma maior compreensão da arquitetura genômica e seu papel na geração das anormalidades estruturais. O objetivo deste trabalho foi sequenciar os pontos de quebra genômicos a fim de identificar o mecanismo formador das alterações encontradas. Para isso, investigamos o panorama estrutural de 10 pacientes por sequenciamento por meio de linked reads (10X Genomics) e sequenciamos os pontos de quebra previamente identificados por array CytoSNP-12 (Illumina) de 12 pacientes com rearranjos genômicos estruturais por utilizando a captura por Nextera Rapid Capture (Illumina). A investigação por linked reads revelou rearranjos estruturais em 5 pacientes, destacando translocações encontradas em dois pacientes, impossíveis de serem detectadas por metodologias de sequenciamento que não envolva long reads. Foi possível sugerir os mecanismos causadores dessas alterações como NHEJ. O sequenciamento após a captura por Nextera foi capaz de identificar elementos que permitiram definir o mecanismo em três pacientes (NAHR E FoSTeS/MMBIR) e sugerir em mais dois pacientes (NHEJ). Com a estratégia utilizada foi possível sequenciar pontos de quebra por meio do flanqueamento das regiões identificadas por array, identificar os elementos genômicos presentes nos pontos de quebra e os mecanismos formadores dessas alteraçõesGenomic rearrangements are structural changes in the DNA molecule and can be the cause of numerous genetic diseases. The mechanisms that generate these alterations can occur in different ways. It can be recurrent, mediated by low copy repeats (LCRs), resulting in a rearrangement cause by non-alellic homologue recombination (NAHR), or non-recurrent, without a hotspot. Among non-recurrent mechanisms there are: non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), serial replication slippage (SRS), break-induced serial replication slippage (BISRS), microhomology-mediated break induced replication (MMBIR) and fork stalling and template switching (FoSTeS). Analysis of the breakpoints of genomic rearrangements may provide important information for a better understanding of genomic architecture and its role in generating structural abnormalities. The aim of this work was to sequence the genomic breakpoints in order to identify the mechanism that formed the alterations found. To do this, we investigated the genomic structure of 10 patients by linked reads (10X Genomics) sequencing and sequenced the breakpoints previously identified by Illumina CytoSNP-12 array of 12 patients with structural genomic imbalances by using Nextera Rapid Capture (Illumina). The research by linked reads revealed structural rearrangements in 5 patients, highlighting translocations found in two patients, impossible to be detected by sequencing methodologies that did not involve long reads. It was possible to suggest the mechanisms causing these changes as NHEJ. The sequencing after capture by Nextera was able to identify elements that allowed us to determine the formation mechanism in three patients (NAHR and FoSTeS / MMBIR) and to suggest in two patients (NHEJ). With the approach employed here, it was possible to sequencing breakpoints by flanking the regions identified by array, identifying the genomic elements present at breakpoints and the formation mechanisms of the alteration

Cytogenomic assessment of the diagnosis of 93 patients with developmental delay and multiple congenital abnormalities: The Brazilian experience

OBJECTIVE: The human genome contains several types of variations, such as copy number variations, that can generate specific clinical abnormalities. Different techniques are used to detect these changes, and obtaining an unequivocal diagnosis is important to understand the physiopathology of the diseases. The objective of this study was to assess the diagnostic capacity of multiplex ligation-dependent probe amplification and array techniques for etiologic diagnosis of syndromic patients. METHODS: We analyzed 93 patients with developmental delay and multiple congenital abnormalities using multiplex ligation-dependent probe amplifications and arrays. RESULTS: Multiplex ligation-dependent probe amplification using different kits revealed several changes in approximately 33.3% of patients. The use of arrays with different platforms showed an approximately 53.75% detection rate for at least one pathogenic change and a 46.25% detection rate for patients with benign changes. A concomitant assessment of the two techniques showed an approximately 97.8% rate of concordance, although the results were not the same in all cases. In contrast with the array results, the MLPA technique detected ∼70.6% of pathogenic changes. CONCLUSION: The obtained results corroborated data reported in the literature, but the overall detection rate was higher than the rates previously reported, due in part to the criteria used to select patients. Although arrays are the most efficient tool for diagnosis, they are not always suitable as a first-line diagnostic approach because of their high cost for large-scale use in developing countries. Thus, clinical and laboratory interactions with skilled technicians are required to target patients for the most effective and beneficial molecular diagnosis

Characterisation of microbial attack on archaeological bone

As part of an EU funded project to investigate the factors influencing bone preservation in the archaeological record, more than 250 bones from 41 archaeological sites in five countries spanning four climatic regions were studied for diagenetic alteration. Sites were selected to cover a range of environmental conditions and archaeological contexts. Microscopic and physical (mercury intrusion porosimetry) analyses of these bones revealed that the majority (68%) had suffered microbial attack. Furthermore, significant differences were found between animal and human bone in both the state of preservation and the type of microbial attack present. These differences in preservation might result from differences in early taphonomy of the bones. © 2003 Elsevier Science Ltd. All rights reserved